Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR versus LEVEMIR FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR versus LEVEMIR FLEXPEN.
LEVEMIR vs LEVEMIR FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin detemir is a long-acting basal insulin analogue. It binds to insulin receptors, activating downstream signaling pathways that promote glucose uptake in muscle and adipose tissue, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis. The myristic acid side chain enables reversible binding to albumin, resulting in slow and predictable absorption with a prolonged duration of action.
Long-acting insulin analog that activates insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis.
Subcutaneous injection: 0.2 units/kg once daily or twice daily; usual total daily dose 0.5-1.0 units/kg. Adjust based on blood glucose levels.
Subcutaneous injection. Initial dose: 0.2-0.5 units/kg/day once daily or divided into two doses. Titrate by 2-10 units once or twice weekly based on glycemic control. Maximum dose not defined.
None Documented
None Documented
Terminal elimination half-life: 13–18 hours (up to 24 hours with large doses); reflects prolonged absorption from subcutaneous depot due to dihexyl-deamination modification.
Terminal elimination half-life approximately 5-7 hours in children (<6 years: 3-4 hours); provides flat, prolonged pharmacokinetic profile over 24 hours with no pronounced peak.
Renal: minimal, as insulin is extensively reabsorbed and degraded in the proximal tubule; hepatic metabolism: via receptor-mediated endocytosis and degradation by insulin-degrading enzyme; biliary/fecal: negligible.
Renal (30-40% unchanged), remainder hepatically metabolized and excreted in bile/feces; negligible fecal elimination of parent drug.
Category C
Category C
Antidiabetic (Long-Acting Insulin)
Antidiabetic (Long-Acting Insulin)